$7.1 Bn Human Growth Hormone (hGH) Industry Outlook, 2025

DUBLIN, March 20, 2020 /PRNewswire/ -- The "Global Human Growth Hormone Market, by Application, by Distribution Channel, by Region, Industry Analysis and Forecast, 2019 - 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Human Growth Hormone Market size is expected to reach $7.1 billion by 2025, rising at a market growth of 8.3% CAGR during the forecast period.

Growth hormone (GH) treatment has only been used to help children with severe growth hormone deficiency (GHD). Nevertheless, today, with an excess of recombinant human GH (rhGH), it is also used to treat a wide range of other conditions. RhGH may be used to treat short-term GH deficiency (GHD), insufficiency, and other disorders leading to poor growth.

At present, it is also used in patients with chronic renal failure (CRF), Prader Willi syndrome (PWS), Turner syndrome (TS), small gestational age (SGA) with no upward development of 2 years, idiopathic short stature (ISS) and some short-term dysmorphic syndromes. Through the growth hormone therapy, many children can attain adult heights better than expected - on the basis of their growth pattern of pretreatment.

Strategies Deployed in Human Growth Hormone (hGH) Market

• Nov-2019: Novartis signed an agreement to acquire The Medicines Company, a biopharmaceutical company. The acquisition is expected to expand the biopharmaceuticals business of the company.
• Jul-2019: Pfizer acquired Therachon, a clinical-stage biotechnology company. The acquisition enabled the company in developing innovtive medicines for addresssing the medical needs of people with rare diseases.
• Jun-2019: Ipsen extended its agreement with Debiopharm for the renewal of their Decapeptyl. Decapeptyl is a natural gonadotropin-releasing hormone (GnRH). Under this partnership, the companies aimed to develop, manufacture, and distribute Decapeptyl across Europe and certain Asian and African markets.
• Mar-2019: Ipsen introduced a new pre-filled syringe for its blockbuster rare disease drug Somatuline (lanreotide) in the EU. Somatuline is used for the treatment of acromegaly, a rare disease caused by excess growth hormone production.
• Jan-2019: Pfizer Mexico came into partnership with JOY, a FamilyTech Wearables Company. Under this partnership, the latter company aims to distribute its first product, the Octopus Watch to the children with a chronic health condition known as growth hormone deficiency (GHD). JOY is expected to distribute its product in Mexico with the help of Pfizer.
• May-2018: Novartis Korea launched Signifor LAR (long-acting release), an acromegaly therapy, on the domestic market. Acromegaly is a rare disease under which the parts of the body grow excessively, resulting in limb enlargement or facial deformity.
• Aug-2017: Teva released generic testosterone, which is used for the treatment of hormone deficiencies and breast cancer. It is also used as a hormone therapy for transgender men.
• Oct-2016: Merck expanded its foothold in Spain by opening a new biotech plant in Tres Cantos, Madrid, Spain. Due to this, the production capacity has been increased by 50%.

Market Segmentation

By Application

• Small for Gestational Age
• Prader-Willi Syndrome
• Idiopathic Short Stature
• Turner Syndrome
• Growth Hormone Deficiency
  
• Pediatric Growth Hormone Deficiency
• Adult Growth Hormone Deficiency
• Other Applications

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• Specialty Pharmacy
• Online Pharmacy

Companies Profiled

• Merck Group
• Teva Pharmaceuticals Industries Ltd.
• Ipsen Pharma Biotech SAS
• Novartis AG (Sandoz International GmbH)
• Pfizer, Inc.
• F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
• Ferring Holdings SA
• Novo Nordisk A/S
• Eli Lilly and Company
• Anhui Anke Biotechnology Group Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/389wt1

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com